Evidence map›Paper›PMID 32051657›Full record

ArticleApplied cognitive psychology

Cognitive testing of an instrument to evaluate acceptability and use of pre-exposure prophylaxis products among women.

Seth Zissette, Millicent Atujuna, Elizabeth E Tolley, Eunice Okumu, Judith D Auerbach, Sally L Hodder, Sevgi O Aral, Adaora A Adimora

Open access · hybridAbstract read
In one paragraph

Article in Applied cognitive psychology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 2 countries.

Seth ZissetteBehavioral, Epidemiological & Clinical Sciences FHI 360 Durham USA.ORCID https://orcid.org/0000-0002-6502-2986
Millicent AtujunaDesmond Tutu HIV Centre University of Cape Town Cape Town South Africa.ORCID https://orcid.org/0000-0003-1287-2634
Elizabeth E TolleyBehavioral, Epidemiological & Clinical Sciences FHI 360 Durham USA.ORCID https://orcid.org/0000-0002-9823-3675
Eunice OkumuBehavioral, Epidemiological & Clinical Sciences FHI 360 Durham USA.
Judith D AuerbachDepartment of Medicine University of California San Francisco School of Medicine San Francisco USA.ORCID https://orcid.org/0000-0003-3216-095X
Sally L HodderSection of Infectious Diseases West Virginia University School of Medicine Morgantown USA.ORCID https://orcid.org/0000-0002-0728-5550
Sevgi O AralDivision of Sexually Transmitted Disease Prevention Centers for Disease Control Atlanta USA.ORCID https://orcid.org/0000-0002-5463-4629
Adaora A AdimoraDepartment of Epidemiology University of North Carolina at Chapel Hill Chapel Hill USA.ORCID https://orcid.org/0000-0001-5035-1552
Family Health International 360 · USDesmond Tutu HIV Foundation · ZAThe Centers · USUniversity of California, San Francisco · USUniversity of North Carolina at Chapel Hill · USWest Virginia University · US

Funding

LOC: HIV Prevention Trials NetworkUM1AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI Sinead Delany-Moretlwe, RAPHAEL J LANDOVITZ · 2011 to 2026
$779.5M
West Virginia IDEA-CTRU54GM104942 · NIGMS · WEST VIRGINIA UNIVERSITY · PI Laura F. Gibson · 2012 to 2026
$81.0M
Ujima Mentoring ProgramP30MH062246 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 2001 to 2026
$57.4M
NIAID NIH HHS UM1 AI068619NIGMS NIH HHS U54 GM104942NIMH NIH HHS P30 MH062246
6 · The paper itself

Abstract

Given the range of pre-exposure prophylaxis (PrEP) products currently being tested to prevent HIV in women, a standardized Acceptability and Use of PrEP Products Among Women Tool may facilitate comparisons of product acceptability and use across different geographies, trials, and users. We conducted three rounds of cognitive interviewing over 2 months in 2016, with 28 South African women who had experience participating in a range of PrEP product trials. The final instrument contained 41 items, including five new items that improved construct validity and 22 items modified for clarity. Changes were made due to unclear wording, difficulty answering, participant embarrassment, low response variability, and administrative formatting. Cognitive interviewing provided a means to address issues that would have inhibited this tool's ability to accurately collect data otherwise. This rapid, low-cost study provided valuable insight into participants' understanding of questions and demonstrated the utility of cognitive interviewing in international clinical trials.

Indexed as

acceptabilityclinical trialscognitive interviewingHIV preventionPrEP

Identifiers

PMID32051657
PMCPMC7003830
OpenAlexW2956383231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.